These changes include: Declining estrogen levels that promote visceral fat accumulation Accelerated loss of fat-free mass Approximately 2-3% decline in resting metabolic rate per decade after age 20 Disrupted sleep patterns that further impair metabolism GLP-1 receptor agonists offer a particularly compelling approach for addressing menopause-related weight challenges by: Directly targeting the visceral adiposity that characterizes menopausal weight gain Countering metabolic slowdown through enhanced satiety signals Improving insulin sensitivity and glucose metabolism Potentially complementing hormone replacement therapy (HRT) The relationship between GLP-1RAs and HRT deserves special attention
Jeff Atlas, PA-C, works through each patients history, goals, and bloodwork before any treatment plan begins
3.7.3 hCG hCG-containing products on the market include Pregnyl, Vir-Provigil, Ovigil, HCG 5000 IU, Gonadonax 5,000, Chorgon Human Chorionic, Puretrig-5000 IU
With currently available GLP-1 receptor agonists an HbA1c target of less than 7.0% was obtained by 51%-79% of subjects and a body weight loss of 10% was only achieved by 4% to 27%, illustrating the need for more potent therapeutic medications
Conversely, THC in cannabis is well known to stimulate appetite, potentially counteracting tirzepatide's appetite-suppressing effects
This predictability is gold in a research setting
